Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050865 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
A Phase 3 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT04050865 is a Phase 3 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 96 participants.
The verdict
NCT04050865, a Phase 3 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
Interventions
- DRUG Dexamethasone, 0.4mg
- DEVICE Placebo plug with no drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2020-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050865
The ClinicalTrials.gov registry entry for NCT04050865 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocular Therapeutix, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone, 0.4mg is the first listed.
NCT04050865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04050865 about?
NCT04050865 is a clinical study titled "A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis". The objective of the study is to evaluate the efficacy and safety of OTX-DP as a dexamethasone ophthalmic insert when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of allergic conjunctivitis.
What is the current status of trial NCT04050865?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2019-08-05. Estimated completion is 2020-02-28.
What interventions are being tested in trial NCT04050865?
The interventions under investigation include: Dexamethasone, 0.4mg (DRUG), Placebo plug with no drug (DEVICE).
Who is sponsoring clinical trial NCT04050865?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.